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 1 
What This Study Adds to the Field: COPD alveolar macrophages (AM) have a 1 
specific defect in opsonic phagocytosis which correlates with clinical phenotype. 2 
COPD AM fail to engage an anti-oxidant transcriptional module following exposure 3 
to opsonized bacteria. Agonists of a key transcriptional regulator of anti-oxidant host 4 
defense, Nrf2, reverse the opsonic phagocytosis defect in COPD and offer a potential 5 
therapeutic approach to correct the defect. 6 
 7 
Footnote: 8 
3UHVHQWHGLQSDUWDV³COPD alveolar macrophages have a defect in opsonic 9 
phagocytosis of serotype 14 Streptococcus pneumoniae´. M.Bewley, R.Budd, 10 
D.Singh, P.J. Barnes, L.E. Donnelly, D.H.Dockrell and M.K.Whyte. American 11 
Thoracic Society International Conference San Diego May 18th, 2014. Am J. Respir 12 
Crit Care Med 189:2014; A1011 13 
 14 
This article has an online data supplement, which is accessible from this issue's table 15 
of content online at www.atsjournals.org 16 
  17 
 2 
Abstract  1 
Rationale: Previous studies have identified defects in bacterial phagocytosis by 2 
alveolar macrophages (AM) in patients with chronic obstructive pulmonary disease 3 
(COPD) but the mechanisms and clinical consequences remain incompletely defined. 4 
Objectives: To examine the effect of COPD on AM phagocytic responses and 5 
identify the mechanisms, clinical consequences and potential for therapeutic 6 
manipulation of these defects. 7 
Methods: We isolated alveolar macrophages (AM) and monocyte-derived 8 
macrophages (MDM) from a cohort of COPD patients and controls within the MRC 9 
COPD-MAP consortium and measured phagocytosis of bacteria in relation to opsonic 10 
conditions and clinical features. 11 
Measurements and Main Results: COPD AM and MDM have impaired 12 
phagocytosis of S. pneumoniae. COPD AM have a selective defect in uptake of 13 
opsonized bacteria, despite the presence of anti-pneumococcal antibodies in 14 
bronchoalveolar lavage, not observed in MDM or healthy GRQRU¶V$0. AM defects in 15 
phagocytosis in COPD are significantly associated with exacerbation frequency, 16 
isolation of pathogenic bacteria and health related quality of life scores. Bacterial 17 
binding and initial intracellular killing of opsonized bacteria in COPD AM was not 18 
reduced. COPD AM have reduced transcriptional responses to opsonized bacteria, 19 
including cellular stress responses that include transcriptional modules involving 20 
antioxidant defenses and Nrf2-regualted genes. Agonists of the cytoprotective 21 
transcription factor Nrf2 (sulforaphane and Compound 7) reverse defects in 22 
phagocytosis of S. pneumoniae and non-type able Haemophilus influenzae by COPD 23 
AM.  24 
Conclusions: Patients with COPD have clinically relevant defects in opsonic 25 
 3 
phagocytosis by AM, associated with impaired transcriptional responses to cellular 1 
stress, which are reversed by therapeutic targeting with Nrf2 agonists.  2 
 4 
Introduction.  1 
 2 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung 3 
condition characterised by progressive airflow limitation (1, 2). COPD is associated 4 
with increased susceptibility to bacterial airway infection. Exacerbations cause acute 5 
worsening of symptoms, leading to hospitalization (3) and to disease progression (4). 6 
Approximately 50% of exacerbations are due to bacterial infection (5) and, in a long-7 
term cohort study, the lower airways were chronically colonized with Streptococcus 8 
pneumoniae in a third of patients (6). Individuals living with COPD are also at 9 
increased risk of community-acquired pneumonia (CAP) with increased mortality, 10 
most often caused by S. pneumoniae (7). This suggests COPD leads to an innate 11 
immune defect against S. pneumoniae and other bacteria. 12 
 13 
Alveolar macrophages (AM) are the resident phagocytes enabling bacterial clearance 14 
from the lung, but COPD AM demonstrate reduced phagocytosis of Haemophilus 15 
influenzae and P. aeruginosa (8, 9), while COPD monocyte-derived macrophages 16 
(MDM) show impaired phagocytosis of S. pneumoniae (10). Bacterial phagocytosis 17 
by macrophages involves both non-opsonic and opsonic pathways (11, 12). Previous 18 
studies of COPD macrophages have examined non-opsonic or complement-mediated 19 
phagocytosis but phagocytosis in the presence of opsonizing antibody has not been 20 
studied in detail. A specific defect in opsonic phagocytosis would be particularly 21 
relevant to capsulated micro-organisms, such as S. pneumoniae, which require 22 
opsonization for efficient phagocytosis (13), involving both IgG and complement 23 
present in alveolar fluid (14).  24 
 25 
 5 
We investigated mechanisms underlying phagocytic defects in the COPD lung. COPD 1 
Opsonization fails to enhance AM phagocytosis, although it enhances MDM 2 
phagocytosis. The level of AM opsonic phagocytosis was strongly associated with 3 
clinical and microbiological phenotype. AM responses to opsonized S. pneumoniae 4 
activated cellular stress transcriptional responses to antioxidant responses, but these 5 
were abrogated in COPD AM. Agonists of the antioxidant transcription factor, 6 
nuclear factor (erythroid-derived2) like 2 (NFE2L2) or Nrf2, a prominent component 7 
of antioxidant transcriptional responses, corrected the defect in AM opsonic 8 
phagocytosis in COPD. Some of the results of these studies have been previously 9 
reported in the form of an abstract (15). 10 
  11 
 6 
Methods 1 
Macrophage donors: COPD patients, free from exacerbation, were recruited from the 2 
UK Medical Research Council (MRC) COPD-MAP consortium with written 3 
approved consent, as outlined online.  4 
 5 
Cells and Infection: AM were isolated from broncho-alveolar lavage (BAL) as 6 
previously described (13) Cells were >95% AM as assessed by Diff-Quick staining 7 
(Dade Behring) visualised by light microscopy (Leica DMRB 1000). Human MDM 8 
were differentiated for 14 d from peripheral blood mononuclear cells isolated from 9 
donors with written informed consent by Percoll (Sigma) gradient. Cells were 10 
cultured in RPMI (Lonza) supplemented with 10% FCS with low LPS (Lonza). Some 11 
cells were incubated with 10 PM of sulforaphane, 0.065 PM Compound 7, a selective 12 
inhibitor of the Kelch-like ECH-associated protein 1 (KEAP1) /Nrf-2 interaction 13 
(16),  or vehicle control for 16 h before challenge with bacteria. 14 
 15 
Bacteria: Serotype 14 S. pneumoniae (NCTC11902) represents a serotype commonly 16 
causing infection in COPD (17). Stocks were grown as previously described (18). 17 
Non-typeable H. influenzae (NCTC 1269) was cultured as outlined in the online 18 
supplement. Macrophages were infected at a multiplicity of infection (MOI) of 10:1. 19 
S. pneumoniae were opsonized for 15 min. with immune serum obtained from 20 
volunteers vaccinated with pneumococcal polysaccharide vaccine, and with detectable 21 
antibody levels against S. pneumoniae, prior to macrophage challenge (13). Viable 22 
intracellular bacteria were measured at 4 h post-challenge as a measure of bacterial 23 
internalization using a gentamicin protection assay (GPA) as previously described 24 
(19). For assessment of early S. pneumoniae killing, macrophages were challenged for 25 
 7 
4 h before GPA, while additional wells were placed in media containing 0.75 µg/ml 1 
vancomycin before GPA at the designated time points. 2 
 3 
Bacterial binding: Bacterial binding and internalisation were assessed by fluorescence 4 
microscopy (Leica DMRB 1000) (13). Detailed information can be found in the 5 
online supplement.   6 
 7 
Cell surface marker expression.  Cell surface marker expression was measured by 8 
flow cytometry, as described online.  9 
 10 
Transcriptomic analysis: RNA was extracted and hybridized onto the Affymetrix HG-11 
U133 plus 2.0 Array. Data were analysed in R using affyPML and Limma. 12 
Enrichment analysis of Gene Ontology (GO) terms using a Hypergeometric model 13 
using GOstats package in R was performed for differentially expressed genes. False 14 
discovery rates (FDR) were corrected with the Benjamini-Hochberg procedure. More 15 
detailed information is included in the online supplement. 16 
  17 
Western blot: Whole cell extracts were isolated using SDS-lysis buffer and separated 18 
by SDS gel electrophoresis, as described in the online supplement.  19 
 20 
Statistics: Results are recorded as mean and SEM.  Sample sizes were informed by 21 
standard errors obtained from similar assays in prior publications  (13, 18)Decisions 22 
on use of parametric or non-parametric tests were based upon results of  D'Agostino-23 
Pearson normality tests.   Comparisons were made by paired student t-test and 24 
 8 
correlations determined E\6SHDUPDQ¶VWHVWXVLQJPrism 6.0 software (GraphPad Inc.). 1 
Significance was defined as P < 0.05.  2 
 3 
 4 
5 
 9 
Results 1 
Demographic data for macrophage donors. 2 
The demographic features for the COPD-MAP macrophage donors are listed in Table 3 
1. The COPD patients had a significantly greater number of pack years of cigarette 4 
exposure. Sixteen of 42 COPD patients (38.1%) had a history of frequent 5 
exacerbations 2/year). Vaccine history was available in 69% and of these 83% of 6 
COPD patients had received a pneumococcal vaccine. 7 
 8 
COPD AM have selective defects in phagocytosis of opsonized S. pneumoniae. 9 
Both COPD AM and MDM demonstrated reduced intracellular numbers of S. 10 
pneumoniae compared to healthy controls, irrespective of opsonic conditions (Figure 11 
1A-D). COPD AM (but not MDM) from frequent exacerbators had reduced 12 
intracellular bacteria, irrespective of opsonic conditions (Figure 1A-D). Frequent 13 
exacerbation was set DW2 exacerbations/yr. and as shown in Figure E1 patients with 14 
only one exacerbation did not have a reduction in bacteria uptake, while those with 15 
did. Paired analysis of intracellular bacteria numbers, comparing MDM with AM 16 
from the same donor, showed that intracellular S. pneumoniae were lower in AM than 17 
MDM in COPD (but not healthy groups,) regardless of opsonic condition or 18 
exacerbation frequency (Figure 1E-F). Opsonization significantly increased numbers 19 
of intracellular bacteria in all MDM groups, but significantly increased numbers only 20 
in healthy, not COPD, AM (Figure 1G-H). 21 
 22 
The number of viable intracellular S. pneumoniae is influenced by both phagocytosis 23 
and the rate of early intracellular killing (13). To establish that lower intracellular 24 
viable bacteria in COPD AM were not due to alterations in bactericidal activity, we 25 
 10 
measured the kinetics of intracellular killing. Opsonization did not alter the rate of 1 
bacterial killing in any macrophages (Figure E2A-D). Opsonization appropriately 2 
increased both the percentage of healthy AM binding bacteria, and also the 3 
number of internalized bacteria binding per macrophage but did not enhance 4 
uptake in COPD (Figure E3). Binding of non-opsonized or opsonized S. pneumoniae 5 
was not altered by COPD or exacerbation frequency. Surface expression of FcJ 6 
receptors, CD16, CD32 and CD64 were similar in AM/MDM of COPD patients and 7 
controls (Figure E4A-B). Studies have demonstrated a central role for the Exchange 8 
protein activated by cAMP 1 (Epac-1) in the inhibition of Fc-J receptor-mediated 9 
phagocytosis (20). However, AM expression of Epac-1, or of its primary target Rap-1 10 
(21) was unaltered by S. pneumoniae challenge or by COPD (Figure E4C-D).  11 
Similarly, there was no difference in expression of Rac1, a Rho-family GTP-12 
binding protein that regulates lamellipodia formation and membrane ruffling in Fc 13 
receptor-mediated phagocytosis in AM (22).  14 
 15 
Since COPD AM demonstrate a specific defect in opsonic phagocytosis we confirmed 16 
if patient bronchoalveolar lavage fluid (BAL) samples had significant levels of anti-17 
pneumococcal antibodies. We measured antibodies against the 13 serotypes included 18 
in Prevnar-13, a licensed protein conjugate vaccine, using a sensitive multiplex 19 
immunoassay. Unconcentrated BAL samples had detectable pneumococcal antibodies 20 
to 2.9 ± 0.5 serotypes and 72% of samples had antibody against at least one serotype, 21 
with a range of 0-9 serotypes. Antibodies were most common to serotypes 3 (38%), 22 
serotype 14 (45%) and serotype 19A (45%), see Figure E5. More specifically for the 23 
COPD sample 73% had detectable antibodies to 1 or more serotypes. 24 
 25 
 11 
Decreased opsonic phagocytosis in COPD is associated with bacterial 1 
colonisation and correlates with clinical features. 2 
COPD lungs are often colonized with bacteria, most often H. influenzae and S. 3 
pneumoniae (23), and colonization is associated with increased exacerbation 4 
frequency (6). Since AM are essential mediators of pulmonary innate immunity (24),  5 
we established whether AM phagocytic defects were associated with bacterial 6 
colonization. We found that COPD patients who were culture-positive for pathogenic 7 
micro-organisms (PPMs) in their sputum had significantly lower levels of AM 8 
phagocytosis for opsonized, but not non-opsonized S. pneumoniae, when compared to 9 
culture-negative patients (Figure 2A-B). In contrast, using qPCR to identify 10 
pathogenic micro-organisms in BAL, we determined that PCR-positive samples were 11 
not associated with lower levels of opsonic or non-opsonic AM phagocytosis of S. 12 
pneumoniae (Figure 2C-D).  13 
 14 
Correlation analysis of non-opsonized and opsonized phagocytosis of S. pneumoniae 15 
against FEV1 showed that there was a significant relationship between FEV1 and 16 
levels of opsonic phagocytosis, but not non-opsonic phagocytosis (Figure 3A-B). 17 
However, since FEV1 correlates poorly with symptoms in COPD (25), we also looked 18 
to see if AM phagocytosis levels were related to scores from health-related quality of 19 
life (HR-QoL) instruments, the St George's Respiratory Questionnaire (SGRQ), 20 
COPD Assessment Test (CAT) or with the 6-minute walking distance (6MW). For the 21 
SGRQ and CAT score (although not for the 6MW), there was a significant correlation 22 
between impaired opsonic phagocytosis and scores representative of increased 23 
symptom severity but, in contrast, non-opsonic uptake was not correlated with any 24 
 12 
HR-QoL score, suggesting it was less tightly associated with COPD symptoms 1 
(Figure 4A-F).  2 
COPD AM have reduced transcription of antioxidant genes induced in response to 3 
opsonized bacteria. 4 
To provide further insights into the mechanisms influencing the selective defect in 5 
opsonic phagocytosis in AM we next looked at the transcriptional response of AM 6 
to opsonized S. pneumoniae. There are significantly fewer differentially expressed 7 
genes in the COPD AM in response to infection than in healthy AM (Figure 5A). 8 
Table E1-2 shows the top ten upregulated and downregulated gene probes in 9 
healthy and COPD AM respectively. We reviewed the enriched GO terms and 10 
noted fewer terms differentially regulated in COPD and lower levels of induction 11 
(Figure 5B).  We also observed that, within the Biological Processes differentially 12 
regulated, although the GO term relating to the cellular response to stress was 13 
prominently enriched in healthy AM, it comprised significantly fewer components 14 
in the COPD AM (supplemental Table E3). Included in this response are a series 15 
of genes regulating antioxidant defense, which were prominent in the genes altered 16 
in healthy AM (Figure 5C, supplemental Figure E6 and supplemental Table E4), 17 
but these showed comparatively less differential regulation in in COPD.   18 
Although these responses are not recognized as a major feature of innate host 19 
responses to bacteria, antioxidant responses modulate inflammatory responses. 20 
These antioxidant responses are activated by a variety of sources of oxidative 21 
stress including microbicidal responses to bacteria and baseline reductions in 22 
antioxidant responses  are previously described in COPD (26).  23 
 24 
 13 
Activation of Nrf2 increases phagocytosis of non-opsonized and opsonized S. 1 
pneumoniae in AM but not MDM. 2 
Increased oxidative stress in the COPD lung has been associated with impairment 3 
of phagocytosis of non-opsonized unencapsulated bacteria and apoptotic bodies 4 
(27, 28). The transcription factor Nrf2 is a key regulator of cytoprotective proteins 5 
including antioxidants (29, 30) and treatment of macrophages with a pharmacological 6 
activator of Nrf2, sulforaphane, increases phagocytosis of non-type able H. influenzae 7 
(NTHi) and Pseudomonas aeruginosa in COPD AM (8). Within the differentially 8 
expressed genes in AM following pneumococcal challenge, we identified multiple 9 
Nrf2 regulated genes in healthy AM, but these were not differentially regulated in 10 
COPD AM (Figure 5C and supplemental Table E5).  11 
 12 
Since we identified impairment of an antioxidant transcriptional module we next 13 
tested whether sulforaphane modulated phagocytosis of S. pneumoniae. We 14 
confirmed sulforaphane activated heme-oxygenase (HO-1), an Nrf-2 target gene, in 15 
COPD macrophages (Figure 6A-B) and did not induce either apoptosis or necrosis 16 
in macrophages (Figure E7). Sulforaphane significantly increased numbers of 17 
intracellular bacteria after challenge with non-opsonized S. pneumoniae in both 18 
healthy and COPD AM (Figure 6C), but after challenge with opsonized S. 19 
pneumoniae only in COPD (not healthy) AM (Figure 6D). In contrast, we failed to 20 
demonstrate an uplift in MDM ingestion under any of the conditions studied 21 
(Figure 6E-F). To determine if this pattern occurred with other bacteria, we 22 
confirmed sulforaphane also increased intracellular numbers of NTHi in COPD 23 
AM but not healthy AM/MDM or COPD MDM (Figure 6G-H). We also confirmed 24 
sulforaphane did not alter the rate of early intracellular killing of S. pneumoniae in 25 
 14 
COPD AM (Figure 6I). Moreover, sulforaphane did not significantly induce 1 
expression of Fc-gamma expression (CD16, 32 or 64) in either AM or MDM 2 
(Figure E8). To determine if the uplift in phagocytosis was sulforaphane specific, 3 
cells were also treated with a more specific Nrf2 agonist, Compound 7. This is a 4 
recently described potent and selective inhibitor of the Kelch-like ECH-associated 5 
protein 1 (KEAP1) /Nrf-2 protein-protein interaction (16). Treatment with 6 
Compound 7, also induced expression of HO-1 in COPD MDM in a 7 
concentration-dependent manner (Figure 7A) and also in AM (Figure 7B). 8 
Compound 7 significantly increased phagocytosis of opsonized and non-opsonized 9 
S. pneumoniae by AM (Figure 7C-D). COPD MDM treated with Compound 7 also 10 
showed significant increases in uptake of opsonized bacteria and non-opsonized 11 
bacteria, although increased (Figure 7E-F). Compound 7 did not enhance uptake 12 
by healthy macrophages in any condition. As with sulforaphane Compound 7 13 
treatment did not induce cytotoxic effects (Figure E7B). These findings illustrate 14 
the potential to reverse opsonic phagocytic defects with Nrf2 agonists. 15 
 16 
Discussion 17 
We have demonstrated that COPD macrophages have reduced phagocytosis of 18 
bacteria. Although we observed defects in MDM phagocytic function, failure to 19 
induce phagocytic uplift by opsonization was unique to COPD AM and was the 20 
specific defect that was most predictive of clinical phenotype. COPD AM exposed to 21 
opsonized bacteria had decreased transcriptional responses involving antioxidant 22 
defenses. Importantly AM defects in bacterial uptake were reversed with Nrf2 23 
agonists.  24 
 25 
 15 
Several prior publications have demonstrated COPD is associated with impaired 1 
macrophage phagocytosis of bacteria and apoptotic cells (8, 9, 10, 31). These studies 2 
suggest that there is both a local AM defect but also a systemic defect in macrophage 3 
function, which may arise from a combination of genetic, epigenetic and 4 
environmental factors. Our study extends our understanding by showing an additional 5 
select defect in AM function that inhibits phagocytosis of opsonized bacteria. 6 
 7 
Both complement and immunoglobulin are present in alveolar lining fluid (14). 8 
Pneumococcal-specific IgG is detected in human BAL (32) and is required for 9 
optimal phagocytosis of S. pneumoniae by AM (13). Our study also confirms the 10 
presence of anti-pneumococcal antibodies in unconcentrated BAL, in a COPD 11 
population, in which available data showed >80% vaccination uptake, and an age 12 
matched population some of whom would have had vaccine on the basis of age. 13 
Therefore, a defect in opsonic uptake could reduce the efficacy of vaccination despite 14 
the presence of pneumococcal antibodies in the airway. In a murine model cigarette 15 
smoke reduced complement-mediated S. pneumoniae uptake, but not phagocytosis of 16 
IgG coated beads (33). Impaired phagocytosis of opsonized S. pneumoniae and other 17 
encapsulated bacteria is likely to contribute to COPD pathogenesis. S. pneumoniae 18 
remains a leading cause of exacerbations in COPD (5) and in one study monoculture 19 
of S. pneumoniae proved a specific risk factor for exacerbation (17). S. pneumoniae 20 
also have indirect effects on exacerbations since they promote growth, biofilm 21 
formation and synergy in inflammatory responses with other bacteria causing 22 
exacerbations (34-36). In addition, S. pneumoniae is the major cause of CAP in these 23 
patients (37), and COPD increases the susceptibility and risk of complications with 24 
CAP (7).  25 
 16 
 1 
Recent observations involving polymeric immunoglobulin receptor deficient mice 2 
illustrate how bacterial persistence drives inflammation and small airway remodelling 3 
in a model of COPD (38). Bacterial colonization of the airways is linked to decline in 4 
lung function (6, 39) and recently, bacterial phagocytosis has been shown to correlate 5 
with FEV1 in both COPD (40) and severe asthma (41). Reduced phagocytosis of 6 
opsonized bacteria by AM was observed in patients who were culture-positive, 7 
although PCR-positivity in BAL was not associated with the level of phagocytosis. It 8 
would be of interest in the future to determine if opsonic phagocytosis correlates with 9 
quantitation of PCR but our numbers did not allow this analysis. We used a threshold 10 
of >104 copies/ml to define positivity. Although this threshold ensures sensitivity and 11 
a high negative predictive value in studies on the detection of lower respiratory tract 12 
infection due to organisms such as S. pneumoniae and H. influenzae (42, 43) it may 13 
under estimate colonization. On the other hand, the detection of colonization by PCR 14 
with lower level PCR thresholds is problematic and diagnostic accuracy may be 15 
influenced by increasing numbers of false positive results. Therefore, the sputum 16 
detection may have been more predictive of colonization status. The defect in AM 17 
phagocytosis of opsonized bacteria was more severe in COPD patients with frequent 18 
exacerbations, a factor associated with more rapid decline in FEV1 (44). This could 19 
explain the correlations we observed with more significant impairment of opsonic 20 
phagocytosis observed in patients with lower FEV1 or more severe symptoms with 21 
quality of life assessments. Assessment scales are widely used to describe COPD 22 
patient cohorts and stratify them for interventions, such as pulmonary rehabilitation 23 
(45) and to predict survival (46). Quality of life scales are complementary to FEV1 in 24 
describing disability (e.g. MRC dyspnea scale) or severity of dyspnea symptoms (e.g. 25 
 17 
COPD assessment test) in patients living with COPD and it was noteworthy that the 1 
SGRQ and CAT correlated with the defect for phagocytosis of opsonized bacteria. 2 
FEV1 provides a measure of COPD stage, but correlates poorly with symptoms (25). 3 
This implies the phagocytic defect may be related both to stage and symptoms.  4 
 5 
Future studies will need to identify if the phagocytic defect for opsonized bacteria is 6 
related to a specific receptor pathway or cytoskeletal re-arrangement. A prior study 7 
identified a defect in macrophage receptor with collagenous structure (MARCO) 8 
mediated phagocytosis in COPD (8). This important study identified impaired 9 
phagocytosis of two non-opsonized bacteria (NTHi and P. aeruginosa) in COPD AM 10 
and mice exposed to cigarette smoke and showed that sulforaphane corrected the 11 
defect in an Nrf2-dependent mechanism via enhanced MARCO expression. Our study 12 
in a population with very few current smokers is consistent with these findings 13 
confirming a defect in phagocytosis of non-opsonized bacteria (S. pneumoniae and 14 
NTHi), which is improved by Nrf2 agonists. We extend beyond this showing an 15 
additional defect for opsonized S. pneumoniae. In contrast to the study by Harvey and 16 
colleagues our study highlighted transcriptional changes associated with infection in 17 
healthy and COPD AM rather than the transcriptional effects of sulforaphane, but also 18 
highlights reductions in Nrf2-mediated responses in COPD AM.  The range of 19 
particles, including both opsonized and non-opsonized bacteria and apoptotic bodies, 20 
for which defects have been identified in COPD, argues against involvement of any 21 
single receptor system underlying all these defects. Although MARCO likely 22 
contributes to defects in uptake of non-opsonized bacteria (8), it would not be 23 
anticipated to explain the impairment of opsonized bacteria by AM. An unbiased 24 
approach is more likely to identify mechanisms underpinning the broad systemic 25 
 18 
defect in phagocytosis and the more localized pulmonary defect for opsonized 1 
bacteria.  2 
 3 
The transcriptional responses seen in the healthy AM, in response to S. pneumoniae 4 
included prominent transcriptional responses involving immunometabolism. The 5 
acute responses to bacteria results in a shift to increased glucose uptake and glycolytic 6 
metabolism (47), while glucose diversion via the pentose phosphate pathway is a 7 
well-recognized mechanism of oxidative stress resistance (48). Amongst differentially 8 
expressed metabolic genes increased in healthy but not COPD AM was sirtuin (silent 9 
mating type information regulation 2 homologs) 1, a deacetylase involved in host 10 
responses to M. tuberculosis (49).  Anti-oxidant responses were prominently 11 
upregulated in healthy AM after bacterial infection. Nrf2 regulated genes included 12 
glutamate-cysteine ligase catalytic subunit (GCLC), glutathione-S-transferase zeta 1 13 
(GSTZ-1), glutathione peroxidase 7 (GPX7) and the SLC7A11 gene product, light 14 
chain subunit of the Xc- (xCT) glutamine/cysteine antiporter required, all involved in 15 
glutathione maintenance and utilization, carbonyl reductase 1 (CBR1), 16 
NADPH:quinone oxidoreductase 1 (NQO1), and thioredoxin 2 (TXN2) detoxifying 17 
oxidoreductase enzymes and superoxide dismutase (SOD) 1 (48).  Foxo-regulated 18 
targets including SOD 2 were upregulated, while p53 was also upregulated. Of all 19 
these anti-oxidant responses only p53 was significantly upregulated in COPD AM 20 
after bacterial challenge. We identified upregulation of a series of genes involved in 21 
regulation of ubiquitination (including ubiquitin conjugating E2 enzymes B, D3 and 22 
N), a process controlling signaling via pattern recognition receptors, in healthy AM 23 
after bacterial challenge (50).  Collectively these anti-oxidant responses have the 24 
potential to alter cytokine-induced activation of specific phagocytic pathways, 25 
 19 
expression of receptors or molecules involved in signaling cascades associated with 1 
receptors or the susceptibility of the cytoskeleton to re-arrangements altered by 2 
oxidative stress required for particular phagocytic pathways. It was noteworthy that 3 
the transcriptional response in healthy AM involved downregulation of the class B 4 
scavenger receptor CD36, a receptor for unopsonized particles (51) , which was not 5 
observed in COPD AM. 6 
 7 
The Nrf2 transcription factor regulates a cluster of antioxidant, cytoprotective and 8 
detoxifying genes and influences susceptibility to COPD in murine models involving 9 
cigarette smoke exposure by modifying inflammation and tissue injury (52). We 10 
confirmed prior observations suggesting Nrf2 agonists correct the phagocytic defect 11 
in COPD (8), but extend these by showing they also modulate phagocytosis of 12 
opsonized bacteria. Since this also influenced uptake of non-opsonized particles it is 13 
likely Nrf2 agonists have pleiotropic effects in the modulation of phagocytosis. Nrf2 14 
agonists represent a promising class of agents with which to modulate oxidative stress 15 
in conditions like COPD, particularly with the development of highly-selective agents 16 
that bind to the Kelch domain of KEAP1 and prevent Nrf2 ubiquitination and 17 
proteasomal degradation (16). While sulforaphane activates Nrf2 by targeting 18 
cysteine residues in the BTB domain of KEAP1 and can potentially interact with 19 
other targets (53) we demonstrate significant enhancement of phagocytosis in COPD 20 
macrophages with the selective Nrf2 agonist Compound 7, suggesting this could 21 
represent a potent pharmacological approach with which to correct the COPD 22 
associated defects in phagocytosis. 23 
 24 
In conclusion we have identified that, although COPD induces a systemic defect in a 25 
 20 
range of forms of phagocytosis, a specific defect in phagocytosis of opsonized 1 
bacteria is observed specifically in AM and correlates closely with clinical phenotype 2 
in COPD. Moreover, this defect is amenable to therapeutic targeting with novel and 3 
selective inhibitors of the KEAP1/Nrf2 protein-protein interaction. 4 
 5 
 6 
Acknowledgements. 7 
We would like to thank Prof. Ian Sabroe in setting up ethics approvals for research 8 
bronchoscopies and in for discussions on pulmonary host defense. This report is 9 
independent research supported by National Institute for Health Research (NIHR) 10 
South Manchester Respiratory and Allergy Clinical Research Facility at University 11 
Hospital of South Manchester NHS Foundation Trust and the NIHR Clinical Research 12 
Facility at Sheffield Teaching Hospitals Foundation Trust. The views expressed in 13 
this publication are those of the author(s) and not necessarily those of the NHS, the 14 
National Institute for Health Research or the Department of Health.   15 
 21 
Figure Legends 1 
 2 
Figure 1. COPD AM show deficient opsonic bacterial phagocytosis which 3 
correlates with exacerbation frequency. (A-D) Alveolar macrophages (AM) (A 4 
and B) or monocyte-derived macrophages (MDM) (C and D) from healthy (H) or 5 
COPD (non-frequent (NF) and frequent (F) exacerbators) were challenged with either 6 
non-opsonized (A and C) or opsonized (B and D) serotype 14 S. pneumoniae. 4h post-7 
challenge viable intracellular bacteria were assessed. Values for µQ ¶ IRU +&23'-8 
NF/COPD-F; (A) 18/27/15, (B) 10/19/13, (C) 14/18/12, (D) 14/15/12, ***= p<0.001, 9 
1-way ANOVA. (E-F) A pairwise comparison of phagocytosis of non-opsonized (E) 10 
and opsonized (F) bacteria in MDM and AM from matched donors, ns= not 11 
significant, vDOXHV IRU µQ ¶ IRU +&23'-NF/COPD-F; (E) 11/12/12, (F) 10/11/12, 12 
*=p<0.05, **=p<0.01, ***=p<0.001, paired t-test. (G-H) A pairwise comparison of 13 
phagocytosis of non-opsonized and opsonized S. pneumoniae in matched AM (G) or 14 
MDM (H) donors, vDOXHVIRUµQ ¶IRU+&23'-NF/COPD-F; (G) 10/20/11, (H) 7/8/5, 15 
*=p<0.05, paired t-test. 16 
 17 
Figure 2. Defects in phagocytosis in COPD AM are associated with bacterial 18 
colonisation in the lung. (A-D) Non-opsonic (A and C) and opsonic (B and D) 19 
phagocytosis was stratified into groups dependent on if the donor had negative (-ve) 20 
or positive (+ve) culture of sputum (A and B, n=15 and n=14) or ±ve or +ve (defined 21 
as >104 copies/ml) qPCR of broncho-alveolar lavage (C and D, n=27 and n=26) 22 
UHVXOWVLQGLFDWLYHRIEDFWHULDOFRORQLVDWLRQ S6WXGHQW¶VW-test.  23 
 24 
 22 
Figure 3. Opsonic phagocytosis correlates with FEV1. Non-opsonic (A) and 1 
opsonic (B) phagocytosis rates were correlated against patient FEV1 score. 3HDUVRQ¶V 2 
correlation coefficients (r), and p values, with correlation deemed significant if 3 
p<0.05. n = 36 non-opsonic, 32 opsonic.  4 
 5 
Figure 4. Opsonic phagocytosis correlates with markers of COPD disease 6 
severity. Non-opsonic (A, C and E) and opsonic (B, D and F) rates of phagocytosis 7 
were correlated against patients scores in a variety of markers for COPD disease 8 
severity, the St George's Respiratory Questionnaire (SGRQ) (A and B) (n = 29 non-9 
opsonic, 27 opsonic), COPD Assessment Test (CAT) (C and D) (n = 34 non-opsonic, 10 
30 opsonic) or with the 6-minute walking distance (6MW) (E and F) (n = 14 non-11 
opsonic, 10 opsonic). Values for PearsoQ¶V (r) or Spearman¶V correlation coefficients 12 
(rho) and p values are shown, with correlation deemed significant if p= <0.05. 13 
 14 
Figure 5. Transcriptional response of AM reveals less differential gene 15 
expression in COPD in response to infection.  Alveolar macrophages (AM) from 16 
Healthy or COPD patients were challenged with opsonized serotype 14 S. 17 
pneumoniae (n=3 in each group). 4h post-challenge cell total RNA was collected for 18 
transcriptional analysis. (A) Venn diagram showing the number of probes 19 
differentially expressed in response to infection (moderated t test <0.05, FDR <0.05). 20 
(B) Plots represent the top ten enriched GO biological processes terms and the cellular 21 
response to stress term (in addition the response to oxidative stress term is plotted in 22 
the Healthy AM). The X axis represents enrichment by a hypergeometric test  (±log10 23 
(p value)). The size of the circle and colour represents the number of differentially 24 
expressed genes in that term. Figures generated using NIPA (available 25 
 23 
at https://github.com/ADAC-UoN/NIPA). (C) Volcano plots represent the probe sets 1 
identified from the transcriptomic analysis. Panel a) Healthy: The red triangles are the 2 
GLIIHUHQWLDOO\H[SUHVVHGSUREHVUHODWHG WR WKH³&HOOXODU UHVSRQVH WRVWUHVV WHUP´ZLWK3 
some representative terms named. In blue are the terms associated with the Nrf-2 4 
pathway in the analysis of healthy AM. Panel b) COPD: The red triangles are the 5 
GLIIHUHQWLDOO\H[SUHVVHGSUREHVUHODWHGWRWKH³&HOOXODUUHVSRQVHWRVWUHVV´*2WHUP,Q6 
blue are the terms associated with NRF2 pathway seen in the Healthy analysis.  7 
 8 
Figure 6. Treatment with the Nrf-2 agonist sulforaphane increases non-opsonic 9 
and opsonic phagocytosis in COPD AM but not MDM. (A-B) Alveolar 10 
macrophages (AM) and monocyte derived macrophages (MDM)(B) were pre-treated 11 
with the designated dose of sulforaphane (Sulf) for 16h, before cells were lysed and 12 
probed for expression of heme-oxygenase-1 (HO-1) and actin (n=3). (C-F) AM (C-D) 13 
or MDM (E and F) from healthy (H) or COPD non-frequent (NF) or frequent (F) 14 
exacerbators were pre-treated with vehicle (Sulf -) or Sulforaphane (Sulf +) for 16 h, 15 
before cells were challenged with non-opsonized (C and E) or opsonized (D and F) 16 
serotype 14 S. pneumoniae. 4h post-challenge, numbers of intracellular viable bacteria 17 
were measured, vDOXHVIRUµQ ¶IRU+&23'-NF/COPD-F; (C) 11/19/14, (D) 8/ 10/4, 18 
(E) 9/9/5, (F) 8/9/5, *=p<0.05, paired t-test. (G and H) AM (G) and MDM (H) from 19 
COPD patients or healthy (H) (red lines) donors were pre-treated with sulforaphane 20 
before being challenged with non-typeable H. influenzae (NTHi). 4h post challenge 21 
the numbers of intracellular viable bacteria were measured, vDOXHV IRU µQ ¶ IRU22 
H/COPD (G)3/4, (H) 2/3, *=p<0.05, paired t-test. (I) COPD AM were pre-treated 23 
with sulforaphane (+Sulf) before being challenged with non-opsonized serotype 14 S. 24 
pneumoniae for 4h before extracellular bacteria were killed by the addition of 25 
 24 
antibiotics. At the designated time post-antibiotics, viable bacteria in duplicate wells 1 
were measured to, n=3, no significant difference between vehicle and sulf. 2 
 3 
Figure 7. The Nrf-2 agonist compound 7 also increases phagocytosis in COPD 4 
AM.  5 
(A and B) COPD monocyte-derived macrophages (MDM) (A), or alveolar 6 
macrophages (AM) (B), were pre-treated with the Nrf-2 agonist Compound 7 for 16h 7 
at the designated dose, before cells were lysed and a probed for the expression of 8 
heme-oxygenase-1 (HO-1) by western blot. (C and D) Healthy donor and COPD AM 9 
were pre-treated with Compound 7 at 5x IC50 (0.065 PM), for 16h before being 10 
challenged with opsonized (C), n=3 healthy, n=5 COPD or non-opsonized (D), n=1 11 
healthy, n=10 COPD, serotype 14 S. pneumoniae for 4h, after which numbers of 12 
intracellular viable bacteria were assessed, **=p<0.01, paired t-test. (E and F) 13 
Healthy donor and COPD MDM were pre-treated with compound 7 and challenged 14 
with opsonized (E), or non-opsonized (F), S. pneumoniae as for AM. All n=4, p 15 
**=p<0.01, paired t-test. 16 
 17 
 18 
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Table 1: Demographics of Macrophage Donors 3 
 4 
 Healthy Non-Smoker Healthy Ex-Smoker 
 
COPD 
 
N 12 6 42 
Age (years)                 56 (43-65)              58 (48-69) 66(53-77) 
Gender 6Ƃƃ 2Ƃƃ 7Ƃƃ 
FEV1 Litres 3.19 (2.25-4.77) 2.99 (2.50-3.70) 1.88 (1.00-2.72) 
FEV1 %  110 (74-127) 108 (84-121) 50.8 (32-67) 
FVC litres  3.76 (2.25-5.6) 4.19 (3.45-5.2) 3.49 (1.86-5.24) 
GOLD Stage * N/A N/A 9 GOLD A 
14 GOLD B 
4 GOLD C 
10 GOLD D 
Non-Frequent 
/Frequent** 
N/A N/A NF 26 (0 Exacerbations 
= 19, 1 Exacerbation = 7 
 F 16 (2 Exacerbations 
=3, 3 Exacerbations =7, 
>3 Exacerbations =6) 
Pack Years                  N/A              18 (10-35) 50 (32-67) 
Smoking Status: 
Current/Ex/Never 
0/0/12                     0/6/0 7/35/0 
 
 
Inhaled 
Corticosteroids use 
0 0  35 
 
Vaccine N/A N/A 24 Yes, 5 No, 13N/A 
St George's 
Respiratory 
Questionnaire 
(SGRQ) Total score 
N/A N/A 39.8 (6-83) 
 
   
 
   
COPD Assessment 
Test (CAT) 
N/A N/A 16.3 (4-33) 
6 Minute Walk (m) N/A N/A 400 (264-496) 
